​

Moderna (MRNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRNA Stock Forecast

Moderna stock forecast is as follows: an average price target of $104.90 (represents a 166.31% upside from MRNA’s last price of $39.39) and a rating consensus of 'Hold', based on 26 wall street analysts offering a 1-year stock forecast.

MRNA Price Target

The average price target for Moderna (MRNA) is $104.90 based on 1-year price targets from 26 Wall Street analysts in the past 3 months, with a price target range of $238.00 to $55.00. This represents a potential 166.31% upside from MRNA's last price of $39.39.

MRNA Analyst Ratings

Hold

According to 26 Wall Street analysts, Moderna's rating consensus is 'Hold'. The analyst rating breakdown for MRNA stock is 0 'Strong Buy' (0.00%), 10 'Buy' (38.46%), 14 'Hold' (53.85%), 2 'Sell' (7.69%), and 0 'Strong Sell' (0.00%).

Moderna Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 18, 2024Edward TenthoffPiper Sandler$69.00$37.2785.13%75.17%
Nov 18, 2024Yifeng LiuHSBC$58.00$84.93-31.71%47.25%
Oct 17, 2024Courtney BreenBernstein$55.00$57.46-4.28%39.63%
Oct 14, 2024Michael YeeJefferies$55.00$57.73-4.73%39.63%
Sep 13, 2024Edward TenthoffPiper Sandler$115.00$69.6865.04%191.95%
Sep 13, 2024Luca IssiRBC Capital$75.00$69.687.63%90.40%
Sep 13, 2024Leah Rush CannLoop Capital Markets$238.00$69.68241.56%504.21%
Sep 12, 2024Michael YeeJefferies$65.00$69.68-6.72%65.02%
Sep 12, 2024Cory KasimovEvercore ISI$105.00$67.6855.14%166.57%
Sep 12, 2024Matthew HarrisonMorgan Stanley$94.00$67.5139.24%138.64%
Sep 12, 2024Michael YeeJefferies$120.00$67.5277.74%204.65%
Aug 28, 2024Peter ArmentRobert W. Baird$220.00$78.52180.18%458.52%
Aug 28, 2024Yifeng LiuHSBC$82.00$78.983.82%108.17%
Aug 06, 2024Emmanuel PapadakisDeutsche Bank$80.00$82.30-2.79%103.10%
Aug 05, 2024Luca IssiRBC Capital$90.00$86.583.95%128.48%
Aug 02, 2024Edward TenthoffPiper Sandler$157.00$90.0374.38%298.58%
Jun 12, 2024Hartaj SinghOppenheimer$179.00$148.3920.63%354.43%
Jun 10, 2024Leah Rush CannLoop Capital Markets$310.00$147.47110.21%687.00%
Jun 07, 2024Michael YeeJefferies$180.00$152.0318.40%356.97%
May 31, 2024Luca IssiRBC Capital$160.00$141.8312.81%306.19%
May 13, 2024Cory KasimovEvercore ISI$120.00$125.67-4.51%204.65%
May 09, 2024Emmanuel PapadakisDeutsche Bank$85.00$124.06-31.48%115.79%
May 07, 2024Eliana MerleUBS$151.00$122.1323.64%283.35%
May 03, 2024Michael YeeJefferies$155.00$123.0226.00%293.50%
May 03, 2024Bill MaughanCanaccord Genuity$106.00$125.59-15.60%169.10%
May 03, 2024Hartaj SinghOppenheimer$163.00$125.5929.79%313.81%
May 03, 2024Luca IssiRBC Capital$135.00$125.597.49%242.73%
May 02, 2024Matthew HarrisonMorgan Stanley$95.00$125.00-24.00%141.18%
Apr 24, 2024Matthew HarrisonMorgan Stanley$89.00$108.85-18.24%125.95%
Mar 28, 2024Michael YeeJefferies$125.00$110.5913.03%217.34%
Mar 27, 2024Eliana MerleUBS$143.00$107.4133.13%263.04%
Feb 22, 2024Bill MaughanCanaccord Genuity$82.00$87.59-6.38%108.17%
Feb 22, 2024Matthew HarrisonMorgan Stanley$123.00$87.5940.43%212.26%
Jan 02, 2024Hartaj SinghOppenheimer$142.00$113.1525.50%260.50%
Jun 26, 2023Eliana MerleUBS$191.00$121.1457.67%384.89%
Dec 20, 2022Piper Sandler$217.00$189.8914.28%450.90%
Dec 19, 2022Jefferies$275.00$193.2942.27%598.15%
Dec 16, 2022Morgan Stanley$209.00$191.788.98%430.59%
Dec 14, 2022Chardan Capital$191.00$212.41-10.08%384.89%
Dec 13, 2022Leerink Partners$102.00$197.54-48.36%158.95%
Sep 24, 2022Jasper Hellweg HellwegArgus Research$150.00$123.6421.32%280.81%
May 17, 2022Edward TenthoffPiper Sandler$214.00$142.2850.41%443.29%
May 04, 2022Matthew HarrisonMorgan Stanley$199.00$155.0528.35%405.20%
Apr 01, 2022Edward TenthoffPiper Sandler$348.00$176.5997.07%783.47%
Mar 28, 2022Matthew HarrisonMorgan Stanley$205.00$173.0818.44%420.44%
Mar 08, 2022Emmanuel PapadakisDeutsche Bank$155.00$129.2819.89%293.50%
Feb 27, 2022Michael YeeJefferies$170.00$151.3312.34%331.58%
Feb 24, 2022Gena WangBarclays$210.00$156.2334.42%433.13%
Feb 01, 2022Tyler Van BurenCowen & Co.$200.00$172.7415.78%407.74%
Jan 26, 2022Emmanuel PapadakisDeutsche Bank$175.00$154.9612.93%344.28%
Jan 21, 2022Eliana MerleUBS$221.00$160.0738.06%461.06%
Jan 06, 2022Jasper HellwegArgus Research$350.00$216.0661.99%788.55%
Nov 08, 2021Andrew GallerWolfe Research$304.00$244.6824.24%671.77%
Nov 04, 2021Cory KasimovJ.P. Morgan$165.00$284.02-41.91%318.89%
Jun 29, 2021Nick AbbottWells Fargo$145.00$234.46-38.16%268.11%
May 28, 2021Geulah LivshitsChardan Capital$188.00$185.011.62%377.28%

The latest Moderna stock forecast, released on Nov 18, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $69.00, which represents a 85.13% increase from the stock price at the time of the forecast ($37.27), and a 75.17% increase from MRNA last price ($39.39).

Moderna Price Target by Period

1M3M12M
# Anlaysts2434
Avg Price Target$63.50$59.25$124.15
Last Closing Price$39.39$39.39$39.39
Upside/Downside61.21%50.42%215.18%

In the current month, the average price target of Moderna stock is $63.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 61.21% increase as opposed to Moderna's last price of $39.39. This month's average price target is up 7.17% compared to last quarter, and down -48.85% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2024Evercore ISIReduceDowngrade
Dec 10, 2024HSBCHoldBuyUpgrade
Nov 22, 2024JefferiesHoldHoldHold
Nov 18, 2024Piper SandlerOverweightOverweightHold
Oct 24, 2024Piper SandlerOverweightOverweightHold
Oct 21, 2024Cowen & Co.HoldHoldHold
Oct 17, 2024BernsteinMarket PerformInitialise
Oct 15, 2024Sandler O'NeilUnderperformUnderperformHold
Oct 15, 2024Sandler O'NeillSector PerformSector PerformHold
Oct 14, 2024JefferiesHoldHoldHold
Sep 13, 2024Sandler O'NeillSector PerformSector PerformHold
Sep 13, 2024Piper SandlerOverweightOverweightHold
Sep 13, 2024OppenheimerOutperformPerformDowngrade
Sep 13, 2024RBC CapitalSector PerformSector PerformHold
Sep 13, 2024Brookline CapitalBuyBuyHold
Sep 13, 2024Cowen & Co.HoldHoldHold
Sep 12, 2024JefferiesBuyHoldDowngrade
Sep 12, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Sep 12, 2024JefferiesBuyBuyHold
Aug 28, 2024HSBCReduceHoldUpgrade
Aug 23, 2024Piper SandlerOverweightOverweightHold
Aug 23, 2024Brookline CapitalBuyBuyHold
Aug 15, 2024Sandler O'NeillSector PerformSector PerformHold
Aug 06, 2024Deutsche BankSellHoldUpgrade
Aug 05, 2024RBC CapitalUnderperformSector PerformDowngrade
Aug 02, 2024GuggenheimNeutralNeutralHold
Aug 02, 2024Piper SandlerOverweightOverweightHold
Jun 27, 2024RBC CapitalUnderperformUnderperformHold
Jun 27, 2024UBSBuyBuyHold
Jun 27, 2024Piper SandlerOverweightOverweightHold
Jun 14, 2024Cowen & Co.HoldHoldHold
Jun 12, 2024OppenheimerOutperformOutperformHold
Jun 10, 2024Brookline CapitalBuyBuyHold
Jun 10, 2024Morgan StanleyPositivePositiveHold
Jun 07, 2024JefferiesBuyBuyHold
Jun 06, 2024Piper SandlerOverweightOverweightHold
Jun 03, 2024UBSBuyBuyHold
May 31, 2024RBC CapitalOutperformOutperformHold
May 09, 2024Deutsche BankSellSellHold
May 07, 2024UBSBuyBuyHold
May 03, 2024RBC CapitalBuyBuyHold
May 03, 2024JefferiesBuyBuyHold
May 03, 2024OppenheimerOutperformOutperformHold
May 03, 2024RBC CapitalOutperformOutperformHold
Mar 28, 2024Piper SandlerOverweightOverweightHold
Mar 28, 2024JefferiesHoldHoldHold
Mar 28, 2024RBC CapitalHoldHoldHold
Mar 28, 2024JefferiesBuyBuyHold
Mar 28, 2024Goldman SachsBuyBuyHold
Mar 27, 2024UBSBuyBuyHold
Feb 26, 2024HSBCHoldReduceDowngrade
Feb 23, 2024RBC CapitalHoldHoldHold
Feb 22, 2024OppenheimerNeutralOutperformUpgrade
Feb 22, 2024Canaccord GenuityHoldInitialise
Feb 22, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jan 12, 2024RBC CapitalBuyBuyHold
Nov 03, 2023Goldman SachsBuyBuyHold
Nov 03, 2023HSBCHoldUpgrade
Jul 24, 2023William BlairMarket PerformInitialise
Mar 13, 2023Cowen & Co.OutperformUpgrade
Mar 02, 2023RBC CapitalSector PerformOutperformInitialise
Dec 20, 2022Piper SandlerOverweightOverweightHold
Dec 19, 2022Atlantic EquitiesOverweightUpgrade
Dec 19, 2022JefferiesHoldBuyUpgrade
Dec 16, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Dec 14, 2022Chardan CapitalBuyNeutralDowngrade
Dec 13, 2022OppenheimerNeutralNeutralHold
Dec 13, 2022SVB LeerinkMarket PerformMarket PerformHold
Oct 21, 2022Goldman SachsBuyNeutralUpgrade
Oct 21, 2022RBC CapitalSector PerformDowngrade
Oct 21, 2022Raymond JamesOutperformDowngrade
Oct 21, 2022Keefe, Bruyette & WoodsMarket PerformDowngrade
Oct 21, 2022NeedhamHoldBuyUpgrade
Oct 21, 2022Piper SandlerOverweightNeutralDowngrade
Oct 21, 2022SVB LeerinkUnderperformMarket PerformDowngrade
Oct 18, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Sep 19, 2022CFRABuyUpgrade
Sep 07, 2022Deutsche BankHoldBuyUpgrade
Aug 04, 2022SVB LeerinkUnderperformUnderperformHold
Jun 24, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jun 22, 2022Credit SuisseUnderperformDowngrade
May 17, 2022Piper SandlerOverweightOverweightHold
May 09, 2022NeedhamHoldHoldHold
Apr 29, 2022Brookline CapitalBuyBuyHold
Apr 24, 2022Piper SandlerOverweightOverweightHold
Mar 28, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Mar 14, 2022Piper SandlerOverweightOverweightHold
Mar 07, 2022Deutsche BankHoldHoldHold
Feb 27, 2022JefferiesHoldHoldHold
Feb 25, 2022SVB LeerinkUnderperformUnderperformHold
Feb 24, 2022NeedhamHoldHoldHold
Jan 26, 2022Deutsche BankHoldUpgrade
Nov 28, 2021Piper SandlerOverweightOverweightHold
Nov 13, 2021BarclaysOverweightOverweightHold
Jul 24, 2021Goldman SachsBuyBuyHold
Dec 21, 2020Brookline CapitalBuyBuyHold
Nov 22, 2020BMO CapitalMarket PerformDowngrade
Nov 22, 2020Chardan CapitalBuyUpgrade
Nov 22, 2020Redburn PartnersSellInitialise
Nov 16, 2020OppenheimerOutperformOutperformHold
Nov 16, 2020Piper SandlerBuyBuyHold

Moderna's last stock rating was published by Evercore ISI on Dec 11, 2024. The company Downgrade its MRNA rating from "null" to "Reduce".

Moderna Financial Forecast

Moderna Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$1.83B$344.00M$1.86B$5.08B$3.22B$4.57B$5.94B$7.21B$4.97B$4.35B$1.94B$570.75M$157.91M$66.35M$8.39M$14.05M$17.05M
Avg Forecast$1.51B$1.27B$114.70M$160.30M$1.16B$1.44B$110.66M$137.59M$995.44M$1.25B$128.41M$93.26M$2.51B$1.38B$307.67M$1.18B$5.02B$3.53B$4.10B$4.20B$6.80B$6.08B$4.21B$2.05B$279.41M$80.60M$27.51M$17.60M$17.37M$17.64M
High Forecast$2.20B$1.86B$167.45M$234.02M$1.69B$2.11B$161.55M$158.58M$1.08B$1.27B$128.41M$93.26M$2.91B$1.92B$449.16M$1.72B$7.32B$3.53B$4.10B$4.20B$6.80B$6.08B$4.21B$2.05B$279.41M$80.60M$27.51M$17.60M$17.37M$17.64M
Low Forecast$1.17B$983.29M$88.71M$123.97M$897.34M$1.12B$85.58M$102.03M$917.23M$1.23B$128.41M$93.26M$2.21B$509.40M$237.95M$911.13M$3.88B$3.53B$4.10B$4.20B$6.80B$6.08B$4.21B$2.05B$279.41M$80.60M$27.51M$17.60M$17.37M$17.64M
# Analysts4444333511599101366555111211109987655
Surprise %-------------1.32%1.12%1.58%1.01%0.91%1.11%1.41%1.06%0.82%1.03%0.94%2.04%1.96%2.41%0.48%0.81%0.97%

Moderna's average Quarter revenue forecast for Dec 23 based on 10 analysts is $2.51B, with a low forecast of $2.21B, and a high forecast of $2.91B. MRNA's average Quarter revenue forecast represents a 37.14% increase compared to the company's last Quarter revenue of $1.83B (Sep 23).

Moderna EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333511599101366555111211109987655
EBITDA-------------$-2.01B$-1.87B$-288.00M$1.58B$1.34B$2.45B$4.32B$5.49B$3.63B$3.14B$1.28B$-259.80M$-221.44M$-107.09M$-115.05M$-112.35M$-114.56M
Avg Forecast$-365.05M$-307.57M$-27.75M$-38.78M$-280.69M$-349.46M$-26.77M$-33.29M$-240.81M$-302.42M$-31.06M$-22.56M$-607.47M$-334.93M$-74.43M$-285.00M$-1.21B$-859.55M$-998.59M$3.69B$-1.66B$-1.48B$-1.03B$1.04B$-68.10M$-19.65M$-6.71M$-115.05M$-4.23M$-4.30M
High Forecast$-282.33M$-237.87M$-21.46M$-29.99M$-217.08M$-270.27M$-20.70M$-24.68M$-221.89M$-296.39M$-31.06M$-22.56M$-534.58M$-123.23M$-57.56M$-220.42M$-938.73M$-859.55M$-998.59M$4.43B$-1.66B$-1.48B$-1.03B$1.24B$-68.10M$-19.65M$-6.71M$-92.04M$-4.23M$-4.30M
Low Forecast$-532.93M$-449.02M$-40.51M$-56.61M$-409.77M$-510.17M$-39.08M$-38.36M$-262.21M$-308.44M$-31.06M$-22.56M$-704.67M$-465.15M$-108.66M$-416.07M$-1.77B$-859.55M$-998.59M$2.95B$-1.66B$-1.48B$-1.03B$829.90M$-68.10M$-19.65M$-6.71M$-138.06M$-4.23M$-4.30M
Surprise %-------------6.01%25.08%1.01%-1.30%-1.56%-2.45%1.17%-3.32%-2.45%-3.06%1.23%3.81%11.27%15.97%1.00%26.53%26.64%

6 analysts predict MRNA's average Quarter EBITDA for Mar 23 to be $-285.00M, with a high of $-220.42M and a low of $-416.07M. This is -118.04% lower than Moderna's previous annual EBITDA (Dec 22) of $1.58B.

Moderna Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333511599101366555111211109987655
Net Income-------------$-3.63B$-1.38B$79.00M$1.47B$1.04B$2.20B$3.66B$4.87B$3.33B$2.78B$1.22B$-272.49M$-233.64M$-116.71M$-124.23M$-123.12M$-123.19M
Avg Forecast$-330.93M$-453.78M$-1.15B$-1.07B$-634.71M$-477.99M$-1.27B$-1.25B$-1.11B$-720.00M$-1.34B$3.79B$-393.73M$-770.99M$-1.57B$3.44B$4.60B$1.27B$1.76B$3.13B$3.83B$3.45B$2.29B$991.10M$-131.52M$-145.22M$-135.45M$-124.23M$-161.28M$-167.86M
High Forecast$-233.44M$-320.10M$-809.73M$-756.33M$-447.73M$-337.18M$-893.16M$-1.15B$-702.88M$-507.90M$-942.39M$4.55B$1.62B$-267.05M$-1.11B$4.13B$5.52B$1.27B$1.76B$3.76B$3.83B$3.45B$2.29B$1.19B$-131.52M$-145.22M$-135.45M$-99.38M$-161.28M$-167.86M
Low Forecast$-528.77M$-725.07M$-1.83B$-1.71B$-1.01B$-763.75M$-2.02B$-1.34B$-1.50B$-1.15B$-2.13B$3.03B$-1.37B$-1.49B$-2.51B$2.75B$3.68B$1.27B$1.76B$2.50B$3.83B$3.45B$2.29B$792.88M$-131.52M$-145.22M$-135.45M$-149.08M$-161.28M$-167.86M
Surprise %-------------4.71%0.88%0.02%0.32%0.82%1.25%1.17%1.27%0.97%1.22%1.23%2.07%1.61%0.86%1.00%0.76%0.73%

Moderna's average Quarter net income forecast for Jun 23 is $-1.57B, with a range of $-2.51B to $-1.11B. MRNA's average Quarter net income forecast represents a -2087.27% decrease compared to the company's last Quarter net income of $79.00M (Mar 23).

Moderna SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333511599101366555111211109987655
SG&A-------------$442.00M$332.00M$305.00M$375.00M$278.00M$211.00M$268.00M$201.00M$168.00M$121.00M$77.00M$78.99M$48.54M$36.62M$24.11M$25.63M$28.19M
Avg Forecast$991.37M$835.27M$75.35M$105.31M$762.26M$949.02M$72.70M$90.39M$653.97M$821.27M$84.36M$61.27M$1.65B$909.56M$202.13M$252.33M$190.06M$2.32B$2.69B$229.39M$4.47B$4.00B$2.77B$62.50M$183.74M$53.00M$18.09M$11.57M$11.42M$11.60M
High Forecast$1.45B$1.22B$110.01M$153.74M$1.11B$1.39B$106.13M$104.18M$712.07M$837.63M$84.36M$61.27M$1.91B$1.26B$295.08M$302.80M$228.07M$2.32B$2.69B$275.27M$4.47B$4.00B$2.77B$75.00M$183.74M$53.00M$18.09M$11.57M$11.42M$11.60M
Low Forecast$766.71M$645.99M$58.28M$81.45M$589.52M$733.96M$56.22M$67.03M$602.59M$804.90M$84.36M$61.27M$1.45B$334.66M$156.32M$201.87M$152.05M$2.32B$2.69B$183.52M$4.47B$4.00B$2.77B$50.00M$183.74M$53.00M$18.09M$11.57M$11.42M$11.60M
Surprise %-------------0.49%1.64%1.21%1.97%0.12%0.08%1.17%0.04%0.04%0.04%1.23%0.43%0.92%2.02%2.08%2.24%2.43%

Moderna's average Quarter SG&A projection for Dec 23 is $1.65B, based on 10 Wall Street analysts, with a range of $1.45B to $1.91B. The forecast indicates a 273.24% rise compared to MRNA last annual SG&A of $442.00M (Sep 23).

Moderna EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts4444333511599101366555111211109987655
EPS-------------$-9.53$-3.62$0.20$3.81$2.67$5.55$9.09$12.02$8.27$6.93$3.05$-0.69$-0.59$-0.31$-0.35$-0.37$-0.37
Avg Forecast$-0.83$-1.14$-2.88$-2.69$-1.59$-1.20$-3.17$-3.13$-2.78$-1.80$-3.35$-3.56$-0.99$-1.93$-3.93$-1.75$4.60$3.30$4.58$5.37$9.96$8.97$5.96$2.43$-0.34$-0.38$-0.35$-0.35$-0.42$-0.44
High Forecast$-0.59$-0.80$-2.03$-1.90$-1.12$-0.85$-2.24$-2.88$-1.76$-1.27$-2.36$-2.51$4.07$-0.67$-2.78$-1.23$7.35$3.30$4.58$5.37$9.96$8.97$5.96$2.43$-0.34$-0.38$-0.35$-0.35$-0.42$-0.44
Low Forecast$-1.33$-1.82$-4.60$-4.29$-2.54$-1.91$-5.07$-3.35$-3.75$-2.88$-5.35$-5.68$-3.44$-3.72$-6.29$-2.79$3.25$3.30$4.58$5.37$9.96$8.97$5.96$2.43$-0.34$-0.38$-0.35$-0.35$-0.42$-0.44
Surprise %-------------4.93%0.92%-0.11%0.83%0.81%1.21%1.69%1.21%0.92%1.16%1.25%2.01%1.56%0.88%0.99%0.88%0.85%

According to 6 Wall Street analysts, Moderna's projected average Quarter EPS for Jun 23 is $-3.93, with a low estimate of $-6.29 and a high estimate of $-2.78. This represents a -2067.34% decrease compared to MRNA previous annual EPS of $0.20 (Mar 23).

Moderna Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
ELEVElevation Oncology$0.67$9.001243.28%Buy
CVACCureVac$2.95$29.00883.05%Buy
EDITEditas Medicine$1.52$10.20571.05%Buy
NTLAIntellia Therapeutics$13.13$53.00303.66%Buy
MRNAModerna$40.76$104.90157.36%Hold
NVAXNovavax$9.00$20.33125.89%Buy
BEAMBeam Therapeutics$28.58$55.0092.44%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
VRTXVertex Pharmaceuticals$469.24$533.3013.65%Buy
DNAGinkgo Bioworks$9.61$7.00-27.16%Buy

MRNA Forecast FAQ

Is Moderna a good buy?

No, according to 26 Wall Street analysts, Moderna (MRNA) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 38.46% of MRNA's total ratings.

What is MRNA's price target?

Moderna (MRNA) average price target is $104.9 with a range of $55 to $238, implying a 166.31% from its last price of $39.39. The data is based on 26 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Moderna stock go up soon?

According to Wall Street analysts' prediction for MRNA stock, the company can go up by 166.31% (from the last price of $39.39 to the average price target of $104.9), up by 504.21% based on the highest stock price target, and up by 39.63% based on the lowest stock price target.

Can Moderna stock reach $60?

MRNA's average twelve months analyst stock price target of $104.9 supports the claim that Moderna can reach $60 in the near future.

What is Moderna's current price target trend?

2 Wall Street analysts forecast a $63.5 price target for Moderna (MRNA) this month, up 61.21% from its last price of $39.39. Compared to the last 3 and 12 months, the average price target increased by 50.42% and increased by 215.18%, respectively.

What are Moderna's analysts' financial forecasts?

Moderna's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.85B (high $4.12B, low $2.2B), average EBITDA is $-690M (high $-533M, low $-997M), average net income is $-3.626B (high $-2.828B, low $-5.138B), average SG&A $1.87B (high $2.71B, low $1.45B), and average EPS is $-9.089 (high $-7.088, low $-12.877). MRNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.06B (high $4.46B, low $2.36B), average EBITDA is $-739M (high $-572M, low $-1.079B), average net income is $-3.005B (high $-2.12B, low $-4.801B), average SG&A $2.01B (high $2.93B, low $1.55B), and average EPS is $-7.531 (high $-5.312, low $-12.033).

Did the MRNA's actual financial results beat the analysts' financial forecasts?

Based on Moderna's last annual report (Dec 2022), the company's revenue was $19.26B, beating the average analysts forecast of $16.84B by 14.36%. Apple's EBITDA was $9.77B, beating the average prediction of $620.66M by 1473.81%. The company's net income was $8.36B, missing the average estimation of $10.76B by -22.28%. Apple's SG&A was $1.13B, missing the average forecast of $5.43B by -79.16%. Lastly, the company's EPS was $21.26, beating the average prediction of $17.86 by 19.07%. In terms of the last quarterly report (Sep 2023), Moderna's revenue was $1.83B, beating the average analysts' forecast of $1.38B by 32.25%. The company's EBITDA was $-2.012B, beating the average prediction of $-335M by 500.73%. Moderna's net income was $-3.63B, beating the average estimation of $-771M by 370.82%. The company's SG&A was $442M, missing the average forecast of $909.56M by -51.41%. Lastly, the company's EPS was $-9.53, beating the average prediction of $-1.932 by 393.19%